Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
3.480
+0.020 (0.58%)
At close: Apr 28, 2026, 4:00 PM EDT
3.583
+0.103 (2.96%)
After-hours: Apr 28, 2026, 7:50 PM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 33 employees as of December 31, 2025. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$1,382,333
Market Cap
264.36M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Coherus Oncology | 147 |
| AC Immune | 122 |
| Zentalis Pharmaceuticals | 106 |
| Artiva Biotherapeutics | 104 |
| C4 Therapeutics | 104 |
| Alector | 103 |
| SAB Biotherapeutics | 86 |
ELDN News
- 5 weeks ago - Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - GlobeNewsWire
- 6 weeks ago - Eledon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation - GlobeNewsWire
- 7 weeks ago - NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PRNewsWire
- 7 weeks ago - Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 2 months ago - Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - GlobeNewsWire